Remove Doctors Remove Regulations Remove Trials Remove Vaccine
article thumbnail

COVID-19 Vaccine Developers Adjust Phase 3 Trial Protocols to Allow Authorized Vaccines | 2020-12-17

The Pharma Data

COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data. Pfizer, which has received emergency approvals in the U.S.

Vaccine 52
article thumbnail

FDA Will Follow The Science On COVID-19 Vaccines For Young Children

The Pharma Data

Many parents have questions on COVID-19 and when vaccines are going to be available for youngsters younger than 12 years aged. We are therefore also wanting to see COVID-19 vaccines available for young children. We also know that we all share the interest in ensuring this process is completed with safety at top of mind.

Vaccine 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Deliberate Dysentery

Codon

Today, refined versions of these human challenge studies have become standard practice in testing vaccines for vector-borne diseases (e.g., Human challenge trials were an indispensable part of the development of the malaria vaccine, R21/Matrix-M, endorsed by the World Health Organization last October.

Vaccine 111
article thumbnail

Grifols begins clinical trial of a new treatment that would provide immediate immunity against COVID-19

The Pharma Data

The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination. BARCELONA, Spain , Jan. 18, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P,

article thumbnail

Britain Approves Emergency Use of Pfizer’s COVID Vaccine

The Pharma Data

2, 2020 – Britain became the first Western country to allow emergency use of a coronavirus vaccine on Wednesday, after approving Pfizer’s candidate in the race to inoculate millions of people around the globe. But there are daunting obstacles to the vaccine’s delivery to the masses. WEDNESDAY, Dec.

Vaccine 40
article thumbnail

Biopharma Update on the Novel Coronavirus: October 20

The Pharma Data

Testing Therapies, Antivirals and Vaccines. There has been some discussion of running challenge trials for COVID-19 vaccines. In a challenge trial, people are given a vaccine then intentionally dosed with the virus or bacteria that causes the disease. They will require regulatory and ethical approval.

Vaccine 52
article thumbnail

#ScienceSaturday: April 29, 2023

KIF1A

When clinicians are diagnosing patients the first thing they look at are the symptoms; if KIF1A mutations are most commonly known for spasticity, a doctor might not look for KIF1A mutations in a patient experiencing progressive weakness, which could be a reason for underdiagnosis of KAND. This is important.

Disease 52